To evaluate serum neurofilament light (sNfL) as a prognostic and disease/treatment monitoring biomarker in multiple sclerosis (MS) patients utilizing a large well-characterized cohort of MS patients from Biogen Phase III clinical trials.
No takes yet. Share an insight, caveat, or question.
Calabresi et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: